Bausch Health announced robust third-quarter 2026 financial results, including significant revenue and adjusted EBITDA growth, leading the company to raise its full-year financial guidance. This positive performance, particularly the strong adjusted EBITDA excluding Bausch + Lomb, indicates a healthy operational trajectory and improved profitability.
Bausch Health reported impressive Q3 2026 results, with consolidated revenues up 10% and adjusted EBITDA increasing by 32% year-over-year. The company also highlighted that, excluding Bausch + Lomb, it achieved over $1 billion in quarterly adjusted EBITDA for the first time, signaling strong underlying business performance. This positive financial update led management to raise its full-year guidance, which is a significant positive signal for investors. Short-term, this could lead to increased investor confidence and a potential upward movement in BHC's stock price. Long-term, sustained operational improvements and increased profitability could support further valuation growth. The key opportunity for traders is to capitalize on the positive momentum driven by the raised guidance and strong earnings.